SAN DIEGO & WARREN, N.J.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Bellerophon Therapeutics, Inc. (NASDAQGM: BLPH) violated federal securities laws in connection with its initial public offering ("IPO"). Bellerophon, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.
Bellerophon's Stock Suffers
On February 13, 2015, Bellerophon held its IPO, selling 13 million shares of stock and raising $60 million in new capital. However, since the IPO, Bellerophon's stock has fallen drastically from its offering price of $12 per share to close at only $1.17 per share on October 31, 2016. The decline may be due to the fact that the company's business operations and financial prospects were not as strong as represented in the company's Registration Statement that it filed with the U.S. Securities and Exchange Commission.
View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/bellerophon-therapeutics-inc
Bellerophon Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
